Industry Milestone: Over 15,000 Studies Have Run on Medidata Cloud Platform
October 04 2018 - 6:24PM
Business Wire
Medidata Enables Digital Transformation in Life
Sciences with Largest Data Repository, Powered by AI and Advanced
Analytics
News Summary
- Industry adoption leads to rapid growth
of the Medidata Cloud, now with over 15,000 studies worldwide,
spanning all clinical phases and therapeutic areas
- Over 100,000 life science
professionals are certified on the Medidata platform and over
2 million eLearning courses completed since 2010
- Medidata enables customers to make
data-driven decisions in real time by applying AI and advanced
analytics to the industry's largest, most comprehensive data
repository, with more than 4.4 million patients
Industry’s Largest Ecosystem and Unparalleled Expertise
Accelerate Clinical Research
More than 15,000 studies have been conducted on the Medidata
Cloud, the Intelligent Platform for Life Sciences, Medidata
(NASDAQ: MDSO) announced today, making it the industry’s largest
data repository.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20181004005869/en/
(Graphic: Business Wire)
Ranked as the global leader in life science development software
revenue1, this milestone highlights the company’s position and
experience in the market.
Building upon the most comprehensive data assets in clinical
research, Medidata applies artificial intelligence and advanced
analytics to deliver meaningful insights to over 1,000 customers
across every therapeutic area and clinical phase. More than 100,000
professionals are certified on Medidata’s platform, and over two
million eLearning courses have been completed since 2010.
MEDS & AI: Powering Intelligent Clinical Trials for
Sponsors and CROs
The velocity and variety of data is accelerating in clinical
trials, making integration and standardization more complex than
ever before. To solve for this, Medidata created the Medidata
Enterprise Data Store (MEDS), the largest clinical data repository
with more than 4.4 million patients. Powered by AI, MEDS leverages
innovative technologies to streamline labor intensive steps and
improve decision making in the design, execution and review of
clinical trials.
Over 100 Medidata data scientists, including former FDA
statisticians, designed the Medidata AI framework to optimize the
value of data through advanced machine learning, predictive models
and natural-language processing. MEDS & AI provide important
new insights to clinicians and decision makers in clinical
operations, biostatistics, and data management. Among the
benefits:
- Improve data quality and reduce
timelines and regulatory risk using machine learning that automates
detection of problematic data points
- Optimize protocol design with
data-driven insights from thousands of historical clinical
trials
- Better inform go/no-go decisions
with Medidata Synthetic Control Arms that utilize aggregated data
from previous clinical trials
- Discover biomarkers with machine
learning that mines big data sources
- Boost signal detection with
proprietary algorithms trained with millions of data points
“Our innovative technology, services and data-driven insights
are unmatched in life sciences, allowing us to achieve this
significant industry milestone,” said Tarek Sherif, chairman and
chief executive officer, Medidata. “We built the largest repository
of clinical data and maximize its value through AI and analytics,
to lead digital transformation within our industry.”
“With the life science industry under strong pressure to more
quickly and efficiently bring new drugs to market, the clinical
trial ecosystem is rapidly evolving and expanding. Medidata is
continuing to aggressively invest in growth by strengthening
interoperability, adding new capabilities, and expanding access to
their platform,” says Alan S. Louie, Ph.D., research director, life
sciences, IDC Health Insights.
Learn more about the Medidata Cloud. Join over 1,000 life
science leaders at NEXT NYC on October 24-25. Register today.
1IDC, Worldwide Life Science Software Market Shares, 2017:
Strong, Aggressive Growth Driving Change at the Top, doc
#US43964017, June 2018
About Medidata
Medidata is leading the digital transformation of life sciences
with the world's most-used platform for clinical development,
commercial and real-world data. Powered by artificial intelligence
and delivered by #1 ranked industry experts, the Intelligent
Platform for Life Sciences helps pharmaceutical, biotech, medical
device companies and academic researchers accelerate value,
minimize risk and optimize outcomes. Medidata serves more than
1,000 customers and partners worldwide and empowers more than
100,000 certified users everyday to create hope for millions of
patients. Discover the future of life sciences: www.mdsol.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181004005869/en/
Investors:Betsy Frank,
917-522-4620bfrank@mdsol.comorMedia:Erik Snider,
646-362-2997esnider@mdsol.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Apr 2023 to Apr 2024